GFM
LRMR icon

GF Fund Management’s Larimar Therapeutics LRMR Stock Holding History

GF Fund Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.01K Buy
2,300
+390
+20% +$1.55K ﹤0.01% 556
2026
Q1 		$8.6K Buy
1,910
+230
+14% +$919 ﹤0.01% 571
2025
Q4 		$6.4K Sell
1,680
-161
-9% -$626 ﹤0.01% 608
2025
Q3 		$5.95K Buy
1,841
+258
+16% +$967 ﹤0.01% 599
2025
Q2 		$4.58K Hold
1,583
– – ﹤0.01% 633
2025
Q1 		$3.4K Buy
1,583
+243
+18% +$768 ﹤0.01% 637
2024
Q4 		$5.19K Buy
+1,340
New +$8.85K ﹤0.01% 610

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

GF Fund Management's LRMR Position: Q2 2026 in Review

GF Fund Management increased its Larimar Therapeutics (LRMR) stake by 20% in Q2 2026, buying an estimated $1.55K and bringing the position to 2,300 shares worth $7.01K. The position accounts for ﹤0.01% of the portfolio, ranked #556.

GF Fund Management first reported a position in LRMR in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.6K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • GF Fund Management held 2,300 shares of Larimar Therapeutics worth $7.01K as of Q2 2026.
  • GF Fund Management bought 390 Larimar Therapeutics shares in Q2 2026, an estimated $1.55K.
  • Larimar Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #556 holding.
  • GF Fund Management first reported a position in Larimar Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Larimar Therapeutics position peaked at $8.6K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.